NCT00131352View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Osteoarthritis, KneeMusculoskeletal Diseases
Interventions
DEVICE

hylan G-F 20

Single injection of 6 mL of hylan G-F 20 (Synvisc).

OTHER

Phosphate Buffered Saline

Single injection of 6 mL phosphate buffered saline.

Trial Locations (21)

1070

Hopital Erasme, Brussels

1100

AMC/UVA, Amsterdam

3000

Universitair Ziekenhuis Gastuisberg Leuven, Leuven

4000

CHU Liege, Liège

9000

Universitair Ziekenhuis Gent, Ghent

12850

Institute of Rheumatology, Prague

13005

Hopital de la Conception, Marseille

14059

Faculty Thomayer Hospital, Prague

15006

Faculty Hospital Motol, Prague

31059

Hopital Rangueil, Toulouse

37044

CHU Hopital Trousseau, Tours

41462

Johanna-Etienne Krankenhaus, Neuss

62500

Faculty Hospital Bohunice, Brno

87042

CHU Dupuytren, Limoges

94010

Hopital Henri Mondor, Créteil

6202 AZ

Academisch Ziekenhuis Maastricht, Maastricht

CF14 4XW

University Hospital of Wales, Cardiff

SE5 9RJ

Kings College Hospital, London

M41 5SL

Trafford General Hospital, Manchester

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

OX3 7LD

Nuffield Orthopaedic Centre, Oxford

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00131352 - A Study of the Safety and Efficacy of Hylan G-F 20 (Synvisc) in Patients With Symptomatic Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter